drugset / Trial / NCT07626411

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

NCT07626411

Phase 3 Not yet recruiting 15364 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Timeline

Start
2026-07-31
Primary completion
2029-09-11
Completion
2029-12-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule
Subject REGN7508 Monoclonal antibody

Indications